TLR4 and Sepsis: Docking simulations may also reveal novel multi-target inhibitors—for example, a single polyphenol capable of simultaneously blocking TLR4 dimerization and caspase-3 activation-addressing sepsis heterogeneity more effectively than single-pathway drugs.